Search

Displaying results 5441 - 5450 of 10000 in total
  1. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    Ibudilast is currently in development in the U.S. (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).

  2. Drug

    Cefapirin

    go.drugbank.com/drugs/DB01139
    ApprovedVet approved

    Cefapirin (INN, also spelled cephapirin), commonly marketed under the trade name Cefadyl, is a first-generation cephalosporin antibiotic that is available in injectable formulations. … Production for use in humans has been discontinued in the United States. Cefapirin is partly plasma-bound and is effective against gram-negative and gram-positive organisms.

  3. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  4. Drug

    Velufenacin

    go.drugbank.com/drugs/DB21473
    Investigational

    Velufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder). … Velufenacin has a monoisotopic molecular weight of 362.12 Da.

  5. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Unlike artemether, lumefantrine has a slower onset of action, resulting in clearance of residual parasites and a decrease in recrudescence rate. … Lumefantrine Co-Artemether is a tablet formulation of artemether and lumefantrine, a well-tolerated, fast-acting and effective blood schizontocidal drug that serves primarily in the treatment of uncomplicated

  6. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. … This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).

  7. Drug

    Mimosine

    go.drugbank.com/drugs/DB01055
    Experimental

    Mimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.

    Synonyms: (L)-Mimosine, L-Mimosine
  8. Drug

    anti-alpha5Beta1-integrin antibody

    go.drugbank.com/drugs/DB05870
    Experimental

    The integrin alpha5beta1 has been shown to play a critical role during angiogenesis. anti-alpha5beta1 integrin antibody inhibits angiogenesis, including vessel formation induced by vascular endothelial

  9. Drug

    Afelimomab

    go.drugbank.com/drugs/DB04956
    Experimental

    Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

  10. Drug

    Velaglucerase alfa

    go.drugbank.com/drugs/DB06720
    Approved

    Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease. … Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase.

    Synonyms: GA-GCB